"The evolution of the definition for high-risk multiple myeloma will help identify patients with light chain cast ... involving the immunoglobulin heavy chain (IgH) locus on chromosome 14q32.

Lonza’s bYlok® technology is changing the way bispecific antibodies are designed. Achieving the correct heterodimerization of light and heavy chains during bispecific production can be challenging, ...